296 related articles for article (PubMed ID: 34515195)
1. Survival Outcomes of Gemcitabine Plus S-1 Adjuvant Chemotherapy after Surgical Resection for Advanced Biliary Tract Cancer.
Hosoda K; Fukushima K; Shimizu A; Motoyama H; Kubota K; Notake T; Sugenoya S; Hayashi H; Yasukawa K; Kobayashi R; Soejima Y
Oncology; 2021; 99(11):703-712. PubMed ID: 34515195
[TBL] [Abstract][Full Text] [Related]
2. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202).
Yanagimoto H; Toyokawa H; Sakai D; Wada H; Satoi S; Yamamoto T; Nagano H; Toyoda M; Ajiki T; Satake H; Tsuji A; Miyamoto A; Tsujie M; Takemura S; Yanagihara K; Ioka T
Cancer Chemother Pharmacol; 2018 Mar; 81(3):461-468. PubMed ID: 29305639
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
4. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Morizane C; Okusaka T; Mizusawa J; Katayama H; Ueno M; Ikeda M; Ozaka M; Okano N; Sugimori K; Fukutomi A; Hara H; Mizuno N; Yanagimoto H; Wada K; Tobimatsu K; Yane K; Nakamori S; Yamaguchi H; Asagi A; Yukisawa S; Kojima Y; Kawabe K; Kawamoto Y; Sugimoto R; Iwai T; Nakamura K; Miyakawa H; Yamashita T; Hosokawa A; Ioka T; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Ann Oncol; 2019 Dec; 30(12):1950-1958. PubMed ID: 31566666
[TBL] [Abstract][Full Text] [Related]
5. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Arima S; Shimizu K; Okamoto T; Toki M; Suzuki Y; Okano N; Naruge D; Kawai K; Kobayashi T; Kasuga A; Kitamura H; Takasu A; Nagashima F; Sugiyama M; Furuse J
Anticancer Res; 2017 Feb; 37(2):909-914. PubMed ID: 28179351
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study.
Takahara N; Isayama H; Nakai Y; Sasaki T; Ishigaki K; Saito K; Akiyama D; Uchino R; Mizuno S; Yagioka H; Kogure H; Togawa O; Matsubara S; Ito Y; Toda N; Tada M; Koike K
Invest New Drugs; 2017 Jun; 35(3):269-276. PubMed ID: 28124197
[TBL] [Abstract][Full Text] [Related]
7. Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer.
Kainuma O; Miura F; Furukawa D; Yamamoto H; Cho A; Sano K; Nakagohri T; Asano T
J Hepatobiliary Pancreat Sci; 2015 Nov; 22(11):789-94. PubMed ID: 26234468
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Kobayashi H; Kondo N; Nakagawa N; Sueda T
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):306-13. PubMed ID: 22270151
[TBL] [Abstract][Full Text] [Related]
9. Surgical treatment and adjuvant chemotherapy for patients with biliary tract cancer: single institution experience of 100 patients.
Harada N; Shirabe K; Yoshizumi T; Ikegami T; Uchiyama H; Soejima Y; Yamashita Y; Saeki H; Oki E; Kawanaka H; Morita M; Ikeda T; Matsuura H; Okadome K; Maehara Y
Fukuoka Igaku Zasshi; 2013 Dec; 104(12):539-48. PubMed ID: 24693682
[TBL] [Abstract][Full Text] [Related]
10. Clinical implication of peritoneal cytology in the pancreatic cancer patients who underwent curative resection followed by adjuvant gemcitabine or S-1 chemotherapy.
Aoyama T; Katayama Y; Murakawa M; Shiozawa M; Morimoto M; Yamamoto N; Yoshikawa T; Rino Y; Masuda M; Morinaga S
Hepatogastroenterology; 2015; 62(137):200-6. PubMed ID: 25911897
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma.
Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakamura H; Nakashima A; Sueda T
Ann Surg; 2009 Dec; 250(6):950-6. PubMed ID: 19953713
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of S-1 Adjuvant Chemotherapy for Resected Biliary Tract Cancer: A Retrospective Propensity-Matched Analysis.
Yoshida M; Yanagimoto H; Tsugawa D; Akita M; Urade T; Nanno Y; Fukushima K; Gon H; Komatsu S; Asari S; Kido M; Toyama H; Ajiki T; Fukumoto T
Am Surg; 2024 Jun; 90(6):1279-1289. PubMed ID: 38226586
[TBL] [Abstract][Full Text] [Related]
13. A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01).
Itano O; Takemura Y; Kishida N; Tamagawa E; Shinozaki H; Ikeda K; Urakami H; Ei S; Hayatsu S; Suzuki K; Sakuragawa T; Ishii M; Shito M; Aiura K; Fujisaki H; Takano K; Matsui J; Minagawa T; Shinoda M; Kitago M; Abe Y; Yagi H; Oshima G; Hori S; Kitagawa Y
BMC Cancer; 2020 Jul; 20(1):688. PubMed ID: 32703191
[TBL] [Abstract][Full Text] [Related]
14. A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group.
Kobayashi S; Nagano H; Tomokuni A; Gotoh K; Sakai D; Hatano E; Seo S; Terajima H; Uchida Y; Ajiki T; Satake H; Kamei K; Tohyama T; Hirose T; Ikai I; Morita S; Ioka T;
Ann Surg; 2019 Aug; 270(2):230-237. PubMed ID: 30339627
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer.
Lee KJ; Yi SW; Cha J; Seong J; Bang S; Song SY; Kim HM; Park SW
Cancer Chemother Pharmacol; 2016 Oct; 78(4):841-6. PubMed ID: 27586966
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Li Y; Sun J; Jiang Z; Zhang L; Liu G
J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
[TBL] [Abstract][Full Text] [Related]
17. An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer.
Katayose Y; Ohtsuka H; Kitamura Y; Masuda K; Nakagawa K; Yamamoto K; Yoshida H; Onogawa T; Motoi F; Naitoh T; Rikiyama T; Egawa S; Unno M
Hepatogastroenterology; 2012 May; 59(115):691-5. PubMed ID: 22469710
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
Kim HS; Kim HY; Zang DY; Oh HS; Jeon JY; Cho JW; Park CK; Kim JH; Kim MJ; Ha HI; Kim JH; Han B; Song H; Kwon JH; Choi DR; Jung JY
Cancer Chemother Pharmacol; 2015 Apr; 75(4):711-8. PubMed ID: 25630414
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer.
Ishiwatari H; Hayashi T; Yoshida M; Ono M; Sato T; Miyanishi K; Sato Y; Takimoto R; Kobune M; Kato J
Cancer Chemother Pharmacol; 2015 Apr; 75(4):805-12. PubMed ID: 25687990
[TBL] [Abstract][Full Text] [Related]
20. A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
Suzuki E; Ikeda M; Okusaka T; Nakamori S; Ohkawa S; Nagakawa T; Boku N; Yanagimoto H; Sato T; Furuse J
Cancer Chemother Pharmacol; 2013 May; 71(5):1141-6. PubMed ID: 23525694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]